Skip to content
Clinical Trials – home
Steno Diabetes Center Copenhagen
Sponsor

Steno Diabetes Center Copenhagen

Denmark Borgmester Ib Juuls Vej 83, 2730 Herlev, Denmark

About the sponsor

Research activity centres on type 1 diabetes, with interest in automated insulin delivery, continuous glucose monitoring, exercise-related glucose control, and strategies to reduce hypoglycaemia and glycaemic variability.

  • Insulin therapy optimisation
  • Exercise-induced hypoglycaemia
  • Glucagon-based glucose support
  • Postprandial glucose excursions

Interest also extends to type 1 diabetes with chronic complications and to personalised glucose-lowering approaches in inherited forms of diabetes.

About Specializations

Steno Diabetes Center Copenhagen runs clinical trials in conditions such as Type 1 diabetes mellitus, Monogenic diabetes, Chronic kidney disease, Type 2 diabetes mellitus, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

13 clinical trials

Using glucagon and automated insulin delivery to prevent low blood sugar during exercise in adults with type 1 diabetes

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dasiglucagon
  • Sponsor:Steno Diabetes Center Copenhagen

Increasing the dose of glimepiride for patients with HNF1A-MODY or HNF4A-MODY diabetes

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Glimepiride
  • Sponsor:Steno Diabetes Center Copenhagen

Study on Dapagliflozin, Finerenone, and Semaglutide for Treating Chronic Kidney Disease in Patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Steno Diabetes Center Copenhagen

Study on Using Dapagliflozin, Semaglutide, and Finerenone to Prevent Heart and Kidney Complications in Patients with Type 2 Diabetes

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Steno Diabetes Center Copenhagen

Study on Sotagliflozin for Slowing Kidney Disease in Type 1 Diabetes Patients

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sotagliflozin
  • Sponsor:Steno Diabetes Center Copenhagen

Study on the Effects of Finerenone for Patients with Type 2 Diabetes and Early Diabetic Cardiovascular Autonomic Neuropathy

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Steno Diabetes Center Copenhagen

Study on Reducing Cardiovascular Disease in Type 1 Diabetes Patients Using Finerenone and Semaglutide

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Steno Diabetes Center Copenhagen

Obesity+1

Recruiting

Study on the Effects of Tirzepatide on Heart Health in Overweight and Obese Patients with Coronary Artery Disease

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Saline
  • Sponsor:Steno Diabetes Center Copenhagen

Hypoglycaemia

Recruiting

Study on Sotagliflozin for Treating Low Blood Sugar After Weight Loss Surgery in Patients with Post-Bariatric Hypoglycemia

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Steno Diabetes Center Copenhagen

Monogenic diabetes

Not yet recruiting

Effect of semaglutide added to sulfonylurea on blood sugar in adults with HNF1A‑MODY and HNF4A‑MODY

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Steno Diabetes Center Copenhagen

Diabetic nephropathy+2

Not yet recruiting

Study on Aspirin's Effect on Platelet Aggregation in Patients with Type 1 Diabetes, Atherosclerotic Cardiovascular Disease, and Diabetic Kidney Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Acetylsalicylic Acid
  • Sponsor:Steno Diabetes Center Copenhagen

Chronic kidney disease

Not yet recruiting

Study on the Effects of Finerenone, Dapagliflozin, and Ambrisentan in Patients with Chronic Kidney Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ambrisentan
  • Sponsor:Steno Diabetes Center Copenhagen

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.